OneSource Specialty Pharma Limited has announced its pivotal role in securing Health Canada's approval for a second generic version of semaglutide, marking a significant milestone in the Canadian pharmaceutical market.
On May 4, 2026, OneSource Specialty Pharma Limited, in partnership with Orbicular and a Canadian front-end partner, received approval from Health Canada for a generic version of Ozempic® (semaglutide injection).
This approval positions OneSource partners as the first generic entrants in Canada's semaglutide market, the second-largest globally.
Orbicular led the product development and technical program, while OneSource provided end-to-end manufacturing capabilities. The commercial supply will be supported from OneSource’s US FDA-approved facility in Bengaluru.
This Canadian approval follows a recent tentative approval in the United States, further establishing OneSource's growing presence in complex peptide-based injectable programs. The company is enhancing its ability to support global partners across highly regulated markets.
As per the exchange filings, Mr. Neeraj Sharma, CEO & MD of OneSource, expressed satisfaction with these approvals, highlighting the company's compliance standards and technical expertise in scaling complex drug-device-combination programs.
Building on its success in Canada, OneSource has been supplying multiple brands in India following product launches in March.
The company continues to focus on complex drug-device combinations, biologics, and oral technology, strengthening its position as a global CDMO partner.
OneSource Specialty Pharma Limited is a leading specialty pharmaceutical CDMO, focusing on complex pharmaceutical products such as biologics, drug-device combinations, sterile injectables, and oral technologies.
With 5 state-of-the-art manufacturing facilities and a team of over 1,600 professionals, OneSource has earned the trust of global pharmaceutical companies seeking efficient, end-to-end solutions.
As of April 30, 2026, at 3:30 PM, OneSource Specialty Pharma share price on NSE was closed at ₹1,738.10 down by 1.38% from the previous closing price.
OneSource's involvement in the approval of the second generic semaglutide in Canada underscores its significant role in the pharmaceutical industry. By leveraging its manufacturing capabilities and strategic partnerships, OneSource is poised to continue its impact on the global market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 4, 2026, 9:04 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
